SPAC

Oculis listed on Nasdaq in New York, a first for an Icelandic VC portfolio company

Oculis listed on Nasdaq in New York, a first for an Icelandic VC portfolio company

Last week, Oculis, the Iceland-founded biopharmaceutical company headquartered in Switzerland was officially listed on the Nasdaq stock exchange in New York. Oculis’ shares have now started trading there under the ticker OCS. This makes Oculis the first Icelandic VC portfolio company to go public. Both Klappir and Solid Clouds were

Oculis raises an additional $15M in funding before going public

Oculis raises an additional $15M in funding before going public

The Iceland-founded biopharmaceutical company Oculis which is purposefully driven to save sight and improve eye care with innovations has raised $15M as first reported by Viðskiptablaðið. The participating investors in this newly secured funding round are from Iceland and abroad. This funding adds to the $80M that the company raised

Oculis raises $80M and goes public through a SPAC merger

Oculis raises $80M and goes public through a SPAC merger

Oculis, a global biopharmaceutical company founded by two Icelandic professors at the University of Iceland and European Biotech Acquisition Corp, a special purpose acquisition company (SPAC), have announced they have entered into a definitive business combination agreement. After this transaction, the company will be named “Oculis Holding SA” and will